LAKE FOREST, Calif.--(BUSINESS WIRE)--Oct 6, 2025-- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer ® Lenses (EVO ICL™) for vision correction, today highlighted commentary from numerous independent industry analysts who recognize that STAAR’s merger with Alcon (SIX/NYSE: ALC) – and the compelling, certain, premium cash value it provides – is the best path forward for STAAR stockholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251005004576/en/ Stephen Farrell, CEO of STAAR, said, “Prior to the Alcon transaction, the median sell-side analyst price target for STAAR was only $19.00 per share.